louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04986059: Effects of Pre-event Massage on Muscle Activity
Official title: Effects of Pre-event Massage on Muscle Activity During Jump Activities on Gastrocnemius and Hamstring Muscles
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Neuromuscular Diseases
Keywords: Pre-competition massage
Pre-event massage
Gastrocnemius
Superficial Electromyography
Hamstrings
Lead sponsor: Universitat Internacional de Catalunya
Sponsor class: OTHER
First posted: 2021-08-02
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study observes the effect of a pre-event massage on the gastrocnemius and Hamstring muscles on muscle activity.


Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

* Muscle injury in the last two months
* Suffer a musculoskeletal disorder that doesn't allow the subject to do the study protocol

Primary outcomes:
measure: Muscle activity (microVolts)
timeFrame: Change between baseline(immediately before intervention) and post intervention (immediately after intervention
Secondary outcomes:
measure: Jump Force (Newtons)
timeFrame: Change between baseline(immediately before intervention) and post intervention (immediately after intervention)
measure: Jump speed (m/s)
timeFrame: Change between baseline(immediately before intervention) and post intervention (immediately after intervention)
measure: Jump Height (cm)
timeFrame: Change between baseline(immediately before intervention) and post intervention (immediately after intervention)
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Universitat Internacional Catalunya
state: Sant Cugat
Study officials:
References:
Clinical trial NCT04055259: A Mobile Health and Wellness Coaching Intervention for Weight Loss
Official title: Six-Month Randomized Controlled Trial of Text-Based Mobile Health and Wellness Coaching for Weight Loss
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Overweight and Obesity
Health Behavior
Keywords: Health and Wellness Coaching
Lead sponsor: Edward Via Virginia College of Osteopathic Medicine
Sponsor class: OTHER
Collaborators: name: Auburn University
First posted: 2019-08-13
Enrollment: 60
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study was to assess the effectiveness of a 6-month text-based mobile health and wellness (mHWC) intervention, as compared to usual care (UC), for weight loss in adults. Participants were randomly assigned to one of the two groups (mHWC or UC). At the beginning of the study, both groups were given a Fitbit wearable device, and a weight scale. All participants also received a counseling session from a dietician focused on diet, physical activity, and sleep, and were set up on the Nudge app, a commercially-available mHWC platform. Participants in the mHWC group received text-based coaching messages via Nudge and did not return to the clinic for the duration of the 6-month intervention. Those in the UC group met once a month with a pharmacist or dietician for 6 months. In both groups, the focus was on facilitating health behavior change related to diet, physical activity, and sleep to promote weight loss.

We hypothesized that weight loss at 6 months would be greater in the mHWC group vs. the UC group.


Eligibility criteria: Inclusion Criteria:

* BMI ≥27 kg/m\^2
* Waist circumference ≥35 inches (women) or ≥40 inches (men)
* Own an Android smartphone or iPhone capable of running the Nudge and Fitbit applications.
* Indicate sending at least one text-based (e.g., SMS, Facebook, Twitter) message via their smartphone on most days

Exclusion Criteria:

* Pregnant
* Pacemaker or other electronic implant
* Weight ≥400 pounds
* Weight loss ≥5% of bodyweight in previous 6 months
* High cardiovascular risk, as determined by Physical Activity Readiness Questionnaire (PAR-Q) and physician review, as needed.

Primary outcomes:
measure: Change in Weight
timeFrame: 6 months (mean 193 ± 21 days)
Secondary outcomes:
measure: Change Waist Circumference
timeFrame: 6 months (mean 193 ± 21 days)
measure: Change in Self-Reported Physical Activity
timeFrame: 6 months (mean 193 ± 21 days)
measure: Change in Self-Reported Sleep Quantity
timeFrame: 6 months (mean 193 ± 21 days)
measure: Change in Self-Reported Daily Caloric Consumption
timeFrame: 6 months (mean 193 ± 21 days)
Other outcomes:
Locations:
city: Auburn
country: United States
facility: Auburn University Pharmaceutical Care Center
state: Alabama
Study officials:
affiliation: VCOM-Auburn
name: Joshua C Hollingsworth, PharmD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01005459: Tetracaine Combined Spinal Epidural (CSE) Versus Bupivacaine CSE
Official title: Comparison of Spinal Tetracaine With Fentanyl and Epinephrine Versus Bupivacaine With Fentanyl and Epinephrine for Combined Spinal Epidural Labor Analgesia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Labor Pain
Keywords: labor pain
combined spinal epidural labor analgesia
CSE analgesia
labor analgesia
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2009-11-01
Enrollment: 46
Sex: FEMALE
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators hypothesis is that spinal tetracaine with fentanyl and epinephrine used for CSE labor analgesia volume will last a significantly longer period of time that that of spinal bupivacaine with fentanyl. After informed consent is obtained for the study, subjects meeting criteria when analgesia is requested will be randomized to receive a combined spinal-epidural containing either tetracaine 2 mg with fentanyl and epinephrine or bupivacaine 2 mg with fentanyl and epinephrine.


Eligibility criteria: Inclusion Criteria:

* early labor (\>=2cm but =\<6cm cervical dilation)
* at least 12 years of age
* have an assigned ASA physical status 1 or 2
* singleton pregnancy

Exclusion Criteria:

* contraindications to neuraxial anesthesia
* with allergies to drugs used in the study
* have an assigned ASA status 3 or 4
* advanced labor (\> 6cm cervical dilation)
* less than 12 years of age
* Patients with the potential for distorted epidural anatomy, such as Harrington rods or prior back surgery, will also be excluded.

Primary outcomes:
measure: Spinal Analgesic Duration
timeFrame: 1-2 hrs
Secondary outcomes:
Other outcomes:
Locations:
city: Winston-Salem
country: United States
facility: Forsyth Medical Center- OB Anesthesia dept
state: North Carolina
Study officials:
affiliation: WFUHS
name: Peter H. Pan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02025959: Sleep for Inpatients: Empowering Staff to Act
Official title: Sleep for Inpatients: Empowering Staff to Act
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep Disorders
Sleep
Keywords: staff empowerment
Sleep Apnea
educational intervention
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2014-01-01
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Getting better sleep in the hospital is especially important due to a variety of adverse health effects that can potentially worsen patient recovery.

To address these concerns and improve sleep in US hospitals, we aim to develop the SIESTA (Sleep for Inpatients: Empowering Staff to Act) program as an educational intervention designed to prepare hospital staff to assist patients in obtaining better sleep in hospitals and recognize the importance of screening for sleep disorders. The major educational goals of this proposal is to develop and pilot test an online educational program (SIESTA) which aims to train and motivate medical professionals to provide better sleep for hospitalized patients.

We will utilize data from an ongoing sleep study, performed by the research team at the University of Chicago that looks at how adult patients are able to sleep while they are in the hospital, as a means of education for the participating medical staff.


Eligibility criteria: Inclusion Criteria:

* To be eligible to participate in this study, the subjects must be University of Chicago hospital employees over the age of 18 years old.

Exclusion Criteria:

* We will exclude any hospital staff under the age of 18 years old from this study as well as hospital patients and non-hospital staff.

Primary outcomes:
measure: Impact of Educational program
timeFrame: Four years
Secondary outcomes:
measure: Patient Outcomes
timeFrame: Four Years
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago Medical Center
state: Illinois
Study officials:
affiliation: University of Chicago
name: Vineet M Arora, MD, MAPP
role: PRINCIPAL_INVESTIGATOR
References:
citation: Shear TC, Balachandran JS, Mokhlesi B, Spampinato LM, Knutson KL, Meltzer DO, Arora VM. Risk of sleep apnea in hospitalized older patients. J Clin Sleep Med. 2014 Oct 15;10(10):1061-6. doi: 10.5664/jcsm.4098.
Clinical trial NCT06646159: REThink for Mental Health of the Youths in Romania
Official title: REThink for Mental Health of the Youths in Romania
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Bullying of Child
Bullying Victimisation
Bullying
Lead sponsor: Babes-Bolyai University
Sponsor class: OTHER
First posted: 2024-10-17
Enrollment: 1000
Sex: ALL
Minimum age (years): 10
Maximum age (years): 24
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: In order to test the effect of the intervention, a multi-center randomized control trial (RCT) will be conducted to test the efficacy of the REThink interventions on improving bullying (both victimization and aggression) and mental health compared with a care as usual group. A minimum of 1000 students from the participating institutions (schools will be able to join based on a recruitment call), will be recruited and randomly assigned to either the experimental or control group.


Eligibility criteria: Inclusion Criteria:

* internet and PC access to complete the scales and game

Exclusion Criteria:

* no internet or PC access

Primary outcomes:
measure: Bullying
timeFrame: baseline assessment, one week before starting the intervention
measure: Mental Health
timeFrame: baseline assessment, one week before starting the intervention
measure: Mental Health Stigma
timeFrame: baseline assessment, one week before starting the intervention
measure: Stress
timeFrame: baseline assessment, one week before starting the intervention
measure: Self-compassion
timeFrame: baseline assessment, one week before starting the intervention
measure: Compassion
timeFrame: baseline assessment, one week before starting the intervention
measure: Emotion regulation
timeFrame: baseline assessment, one week before starting the intervention
measure: Trauma Screening
timeFrame: baseline assessment, one week before starting the intervention
measure: Changes in bullying
timeFrame: post-test assessment, one week after finishing the intervention
measure: Changes in mental health
timeFrame: post-test assessment, one week after finishing the intervention
measure: Changes in mental health stigma
timeFrame: post-test assessment, one week after finishing the intervention
measure: Changes in stress
timeFrame: post-test assessment, one week after finishing the intervention
measure: Changes in self-compassion
timeFrame: post-test assessment, one week after finishing the intervention
measure: Changes in compassion
timeFrame: post-test assessment, one week after finishing the intervention
measure: Changes in emotion regulation
timeFrame: post-test assessment, one week after finishing the intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Cluj-Napoca
country: Romania
facility: Babes-Bolyai University
Study officials:
References:
Clinical trial NCT00503659: Comparison of Two Methods of Bronchial Methacholine Provocation
Official title: Comparison of Two Methods of Bronchial Methacholine Provocation: PC 20 FEV1 Versus PD 20 FEV1
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bronchial Hyperreactivity
Bronchial Asthma
Keywords: PC20 FEV1
PD20FEV1
bronchial hyperreactivity
bronchial asthma
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2007-07-19
Enrollment: 48
Sex: ALL
Minimum age (years): 12
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study is meant to compare two routine diagnostic approaches in patients with bronchial asthma. Patients are challenged with methacholine in order to measure their bronchial response. We compare the evaluation of the effects of incremental concentrations versus incremental dosages.

Detailed description: Bronchial methacholine challenge is well established in asthma diagnostic and research purposes. ATS guidelines provide a short five-breath dosimeter protocol using a five-step dilution schedule. The Viasys APS system enables a feasible and less time consuming provocation with incremental dosages. In 48 young adults with bronchial hyperreactivity (BHR) the ATS-protocol with a five-step protocol using a single dilution of 16 mg/ml methacholine should be compared.

Eligibility criteria: Inclusion Criteria:

* Informed consent
* Age 12-45 years
* Known bronchial hyperreactivity

Exclusion Criteria:

* Age \< 12 \> 45 years
* Clinical asthma requiring regular inhalation
* Vital capacity \< 80%
* FEV1 \< 75%
* Chronic disease conditions or infections
* Pregnancy
* Inhalative or systemic steroid use
* Substance abuse
* Incapability of understanding the study's purpose and performance

Primary outcomes:
measure: correlation of the two parameters PC20 FEV1 and PD20 FEV1
timeFrame: feb 2007 - dec 2007
Secondary outcomes:
measure: kappa index of concordance: reliability of the two procedures as to a FEV1 decrease of 20% depending on methacholine concentration
timeFrame: see above
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Goethe University, Department of Pulmonology
state: Hessen
Study officials:
affiliation: Goethe University, Department of Pulmonology
name: Stefan Zielen, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000 Jan;161(1):309-29. doi: 10.1164/ajrccm.161.1.ats11-99. No abstract available.
Clinical trial NCT05395559: Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Official title: Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cognitive Impairment
Dementia
Alzheimer Disease
Delirium
Keywords: Elderly
Hospitalization
Lead sponsor: University Medical Center Groningen
Sponsor class: OTHER
Collaborators: name: ZonMw: The Netherlands Organisation for Health Research and Development
name: Health∼Holland, Topsector Life Sciences & Health
First posted: 2022-05-27
Enrollment: 757
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Patient population:

Dutch-speaking, hospitalized patients aged ≥ 65 years old.

Healthcare professional population:

Nurses and physicians who work at participating wards and take care of one or more participating patients.

Brief summary: The aim of this multicenter, cross-sectional, observational flash mob study is to investigate the prevalence of cognitive impairment in hospitalized elderly aged 65 years or older, and the recognition of cognitive impairment by healthcare professionals.


Eligibility criteria: Inclusion Criteria:

* Dutch-speaking
* Hospitalized
* Age ≥ 65 years old

Exclusion Criteria:

* Unable to perform the Mini-Cog (e.g. due to visual impairment, severe hearing loss, being too ill, or otherwise unable to speak or write)
* Patients who require medical isolation
* Not willing to participate.

Primary outcomes:
measure: Percentage of hospitalized patients aged 65 years or older with cognitive impairment
timeFrame: Baseline
measure: Percentage of hospitalized patients aged 65 years or older with cognitive impairment that has been recognized by nurses, physicians, both their nurse and physician, and either their nurse or physician
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Groningen
country: Netherlands
facility: University Department of Geriatric Medicine
Study officials:
affiliation: University Medical Center Groningen, University Center for Geriatric Medicine
name: Barbara C van Munster, Prof. dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04702659: Chinese Medicine Zhengyi Prescription Tea Bag
Official title: The Study of Clinical Observation About Chinese Medicine Zhengyi Prescription
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Herbal Interaction
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor class: OTHER_GOV
First posted: 2021-01-11
Enrollment: 70
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants have no chronic respiratory disease or those who have been diagnosed as nasal and sinusitis by a doctor, whose clinical diagnosis includes subjects with allergic rhinitis.

Brief summary: Chinese herbal tea bags can adjust physiological functions, help protect power, and give positive energy to the body. This prescription not only focuses on regulating the patient's physical function, but also helps to enhance physical strength.

Detailed description: In Taiwan ,acoording to the TCM theories and viewpoints, Chinese herbal medicine plays an important role in clinical drug application.TCM compound combinations for different diseases, emphasizing the complementarity and balance of ingredients, natural gentleness, uniqueness and efficacy are widely accepted by the public.

Eligibility criteria: Inclusion Criteria:

* Adults over the age of 20, those who have no chronic respiratory disease or those who have been diagnosed as nasal and sinusitis by a doctor, whose clinical diagnosis includes subjects with allergic rhinitis.

Exclusion Criteria:

1. Patient characteristics: age, gender, weight, education level, race, pregnancy and breastfeeding status, smoking, drinking, caffeine, alcohol or drug poisoning, diet and nutritional status, physical limitations, genetic history, etc. Exclude women under the age of 20, unable to order their behavior, pregnant or breast-feeding women
2. Disease characteristics: Subjects who have been diagnosis of mental illness by doctors, as well as long-term diarrhea or long-term use of Chinese medicine.
3. Environmental characteristics: other conditions that make patients unable to cooperate. Such as unsuitability after screening, not signing the subject consent form, etc.

Primary outcomes:
measure: questionnaire-the Chinese Version of the 31-Item Rhinosinusitis Outcome Measure
timeFrame: 28days
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Center for Traditional Medicine, Taipei Veterans General Hospital
Study officials:
affiliation: TaipeiVGH Center for Traditional Medicine
name: chang kaiwei, master
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01609959: New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering
Official title: Effects of the New Angiotensin II Receptor Blocker Azilsartan Versus Valsartan on Blood Pressure in Japanese Patients With Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Keywords: Hypertension
Angiotensin II Receptor Blocker
Azilsartan
Valsartan
Lead sponsor: Nara Medical University
Sponsor class: OTHER
First posted: 2012-06-01
Enrollment: 70
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare blood pressure lowering effect of azilsartan with that of valsartan in Japanese patients with hypertension who have already taken normal-dose angiotensin II receptor blockers.

Detailed description: Hypertension plays a major role in the development of cardiovascular disease. Several guidelines require strict control of blood pressure for preventing cardiovascular events; however, the control is often poor.

A new angiotensin II receptor blocker (ARB), azilsartan, is the first drug which is superior to other ARBs in blood pressure lowering in phase III clinical trials in Japan. We try to evaluate effect of azilsartan on blood pressure lowering in Japanese patients with hypertension who have already taken normal-dose ARBs, and to compare it with that of valsartan.

Eligibility criteria: Inclusion Criteria:

* Hypertensive patients treated with normal-dose angiotensin II receptor blockers (ARBs) in Japan
* Normal-dose ARBs in Japan are defined as follows: losartan potassium 50 mg, candesartan cilexetil 8 mg, valsartan 80 mg, telmisartan 40 mg, olmesartan medoxomil 20 mg, or irbesartan 100mg per day.

Exclusion Criteria:

* Hypersensitivity for azilsartan and valsartan
* Pregnant female
* History of azilsartan use within 3 months

Primary outcomes:
measure: Change in Office Blood Pressure
timeFrame: Baseline and every 2 weeks (up to 12 weeks)
Secondary outcomes:
measure: Change in Home Blood Pressure
timeFrame: Baseline and every 2 weeks (up to 12 weeks)
measure: Change in Renal Function
timeFrame: Baseline and 12 weeks
measure: Change in Fasting Triglyceride
timeFrame: Baseline and 12 weeks
measure: Change in Glycemic Control
timeFrame: Baseline and 12 weeks
measure: Change in Plasma Aldosterone Concentration
timeFrame: Baseline and 12 weeks
Other outcomes:
Locations:
city: Kashihara
country: Japan
facility: First Department of Nara Medical University
state: Nara
Study officials:
affiliation: First Department of Internal Medicine, Nara Medical University
name: Yoshihiko Saito, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: